Cargando…
A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer
To assess clinical utility of the 21-gene assay (Oncotype DX(®) Recurrence Score(®)), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multi...
Autores principales: | Frazier, Thomas G., Fox, Kevin R., Smith, J. Stanley, Laronga, Christine, McSwain, Anita, Paul, Devchand, Schultz, Michael, Stilwill, Joseph, Teal, Christine, Weisberg, Tracey, Vacchino, Judith F., Sing, Amy P., Cherepanov, Dasha, Hsiao, Wendy, Chang, Eunice, Broder, Michael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381203/ https://www.ncbi.nlm.nih.gov/pubmed/25789420 http://dx.doi.org/10.3390/ph8010107 |
Ejemplares similares
-
Characterisation of micrometastatic tumor cells
por: Pantel, K
Publicado: (2000) -
Putative growth characteristics of micrometastatic breast cancer
por: Chambers, Ann F, et al.
Publicado: (2008) -
High-resolution array comparative genomic hybridization of single micrometastatic tumor cells
por: Fuhrmann, Christine, et al.
Publicado: (2008) -
Might positron emission tomography actually treat micrometastatic cancer?
por: Goldstein, Mark R., et al.
Publicado: (2009) -
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance
por: Fehm, Tanja, et al.
Publicado: (2008)